No Data
No Data
Tibet Weixinkang Pharmaceutical (603676.SH): Subsidiary receives drug clinical trial approval notice.
On September 6th, Gelunhui announced that its wholly-owned subsidiary, Beijing Weixinkang Pharmaceutical Research and Development Co., Ltd. (referred to as "Tibet Weixinkang"), has received the approved and issued Drug Clinical Trial Approval Notice for Deoxycholic Acid Injection from the National Medical Products Administration. The deoxycholic acid injection declared by Tibet Weixinkang, a wholly-owned subsidiary of the company, is developed based on Belkyra, a reference preparation marketed by Allergan Pharmaceuticals International/AbbVie S.r.l. Its indication is for improving adults
Tibet Weixinkang Pharmaceutical Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Tibet Weixinkang Pharmaceutical Co., Ltd.
Tibet Weixinkang Pharmaceutical (603676.SH): The net income in the first half of the year was 0.163 billion yuan, a year-on-year increase of 21.98%.
On August 27th, Weixinkang (603676.SH) announced its interim report for the first half of 2024. During the reporting period, the company achieved a revenue of 0.633 billion yuan, a decrease of 15.5% compared to the same period last year; a net income attributable to the parent company of 0.163 billion yuan, an increase of 21.98% year-on-year; a non-GAAP net income of 0.116 billion yuan, a decrease of 11.67% year-on-year; and a basic earnings per share of 0.38 yuan.
Tibet Weixinkang Pharmaceutical (603676.SH) released its half-yearly performance, with a net income of 0.163 billion yuan, an increase of 21.98% year-on-year.
Tibet Weixinkang Pharmaceutical (603676.SH) released its half-year report for 2024, and during the reporting period, the company achieved a revenue of 0.633 billion...
Tibet Weixinkang Pharmaceutical (603676.SH): "Mannitol Fructose Injection" approved for clinical trials.
Tibet Weixinkang Pharmaceutical (603676.SH) announced that its wholly-owned subsidiary, Inner Mongolia Baiyi Pharmaceutical Co., Ltd. has acquired...
No Data